Page last updated: 2024-11-04

oxazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxazepam is a benzodiazepine medication used to treat anxiety, insomnia, and alcohol withdrawal symptoms. It acts as a central nervous system depressant, producing its effects by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. Oxazepam is synthesized through a multi-step process involving the reaction of 2-amino-5-chlorobenzophenone with ethyl chloroformate, followed by a series of reactions to introduce the oxazepam ring system. The compound exhibits anxiolytic, sedative, hypnotic, and muscle relaxant properties, making it useful for managing a variety of anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. Oxazepam is also used for treating insomnia, particularly in patients who have difficulty falling asleep or staying asleep. Additionally, it is effective in managing alcohol withdrawal symptoms, such as anxiety, tremors, and seizures. Extensive research has been conducted on oxazepam to investigate its efficacy, safety, and pharmacological properties. Studies have demonstrated its effectiveness in reducing anxiety symptoms and improving sleep quality. However, oxazepam can also cause side effects, such as drowsiness, dizziness, and impaired coordination, and prolonged use can lead to dependence. The compound is studied to understand its mechanism of action, develop more effective and safer benzodiazepines, and explore alternative treatments for anxiety and related disorders.'

Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4616
CHEMBL ID568
CHEBI ID7823
SCHEMBL ID27435
MeSH IDM0015637

Synonyms (169)

Synonym
oxazepam [usan:usp:inn:ban:jan]
oxazepamum
6gow6dwn2a ,
unii-6gow6dwn2a
ossazepam
nsc169448
serepax
seresta
pacienx
tacepam
murelax
limbial
quilibrex
astress
tazepam
bonare
tranquo-buscopan-wirkstoff
quen
ansioxacepam
drimuel
praxiten
serenid
wln: t67 gmv jn ihj cg iq kr
7-chloro-1,4-benzodiazepine-2-one
2h-1, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-
wy-3498
serax
sobril
adumbran
nsc-169448
isodin
vaben
droxacepam
ro 5-6789
serenid-d
rondar
aplakil
z10-tr
nesontil
cb 8092
serpax
anxiolit
7-chloro-3-hydroxy-5-phenyl-1,4-benzodiazepin-2-one
sedigoa
psiquiwas
propax
hi-long
psicopax
7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one
CHEBI:7823 ,
(+-)-oxazepam
(rs)-oxazepam
2h-1,4-benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-
DIVK1C_000986
KBIO1_000986
nozepam
noctazepam
einecs 210-076-9
hilong
2h-1,4-benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-, (+-)-
oxazepamum [inn-latin]
zaxopam
abboxapam
oxa-puren
(+-)-7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one
1,3-dihydro-7-chloro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one
nsc 169448
dea no. 2835
ossazepam [dcit]
durazepam
anxiolit retard
z 10 tr
azutranquil
hsdb 3140
ccris 488
sigacalm
uskan
wy 3498
n-desmethyltemazepam
alepam
lederpam
oxanid
nortemazepam
tarchomin
IDI1_000986
OPREA1_501459
oxazepam
604-75-1
C07359
NCGC00159323-02
DB00842
serax (tn)
7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one
D00464
oxazepam (jan/usp/inn)
NINDS_000986
inchi=1/c15h11cln2o2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20h,(h,17,19)
adimayptobdmtl-uhfffaoysa-
temazepam impurity, oxazepam-
j3.308a ,
CHEMBL568
oxozepam
oxazepam civ
HMS503E13
7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
NCGC00159323-04
NCGC00159323-03
dtxcid301087
dtxsid1021087 ,
tox21_303501
NCGC00257352-01
cas-604-75-1
tox21_112819
NCGC00258254-01
tox21_111572
tox21_200700
1,3-dihydro-7-chloro-3-hydroxy-5-phenyl-3h-1,4-benzodiazepin-2-one
3h-1,4-benzodiazepin-2-one, 1,3-dihydro-7-chloro-3-hydroxy-5-phenyl-
DF23718500 ,
niosh/df2371850
bdbm85031
nsc_4616
cas_604-75-1
oxazipam
7-chloro-5-phenyl-3h-1,4-benzodiazepine-2,3-diol
gtpl7253
temazepam impurity b [ep impurity]
oxazepam [mart.]
oxazepam [who-dd]
(+/-)-7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one
oxazepam [vandf]
oxazepam [hsdb]
temazepam impurity, oxazepam- [usp impurity]
oxazepam [usan]
oxazepam [usp monograph]
oxazepam [inn]
oxazepam civ [usp-rs]
oxazepam [ep monograph]
2h-1,4-benzodiazepin-2-one, 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-, (+/-)-
oxazepam [jan]
oxazepam [orange book]
oxazepam [mi]
oxazepam [iarc]
SCHEMBL27435
3-hydroxy-1,3-dihydro-7-chloro-5-phenyl-2h-1,4-benzodiazepin-2-one
3-hydroxy-5-phenyl-7-chloro-2,3-dihydro-1h-1,4-benzodiazepin-2-one
(.+/-.)-oxazepam
7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepine-2-one
7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one
7-chloro-3-hydroxy-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one
sr-01000942251
SR-01000942251-1
oxazepam, european pharmacopoeia (ep) reference standard
oxazepam for peak identification, european pharmacopoeia (ep) reference standard
oxazepam 0.1 mg/ml in methanol
oxazepam 1.0 mg/ml in methanol
Q412299
AKOS016347293
oxazepam (usan:usp:inn:ban:jan)
oxazepamum (inn-latin)
oxazepam civ (usp-rs)
temazepam impurity b (ep impurity)
oxazepam (usp monograph)
temazepam impurity, oxazepam-(usp impurity)
oxazepam (ep monograph)
oxazepam (iarc)
oxazepam (mart.)
n05ba04
oxazepam, 1mg/ml in acetonitrile

Research Excerpts

Overview

Oxazepam is a commonly used 1,4-benzodiazepine anxiolytic drug that is polymorphically metabolized in humans. It is a safe, efficient and cheap drug for the treatment of alcohol withdrawal symptoms.

ExcerptReferenceRelevance
"Oxazepam is a short-acting benzodiazepine and one of the most frequently prescribed anxiolytic drugs."( Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects.
Dinis-Oliveira, RJ, 2017
)
1.5
"Oxazepam is a safe, efficient and cheap drug for the treatment of alcohol withdrawal symptoms, but controlled studies are needed to compare its effectiveness with that of clomethiazol."( Oxazepam versus clomethiazol in alcohol withdrawal treatment.
de Millas, W; Ganzer, F; Haasen, C; Kuhn, S, 2010
)
2.52
"Oxazepam is a commonly used 1,4-benzodiazepine anxiolytic drug that is polymorphically metabolized in humans. "( UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
Al-Rohaimi, A; Bekaii-Saab, T; Court, MH; Greenblatt, DJ; Hao, Q; Krishnaswamy, S; von Moltke, LL, 2004
)
1.98
"Oxazepam is a benzodiazepine widely used as a sedative-hypnotic and antianxiety drug. "( Carcinogenicity studies of oxazepam in mice.
Bucher, JR; Haseman, JK; Johnson, JD; Kurtz, PJ; Persing, RL; Shackelford, CC, 1994
)
2.03
"Oxazepam (Serax) is a widely used benzodiazepine anxiolytic agent and a metabolite of other benzodiazepines such as Valium and Librium. "( Pharmacodynamic responses of F344 rats to the mouse hepatocarcinogen oxazepam in a 90-day feed study.
Bucher, JR; Cunningham, ML, 1998
)
1.98
"Oxazepam (Serax) is a tranquilizer-sedative of the benzodiazepine group that is predominantly metabolized to a pharmacologically inactive glucuronide and subsequently excreted by way of the kidneys. "( Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.
Johnson, R; Schenker, S; Shull, HJ; Wilkinson, GR, 1976
)
2.01
"Oxazepam is an anxiolytic with established clinical efficacy. "( Oxazepam: update 1989.
Ayd, FJ, 1990
)
3.16
"Oxazepam is a useful oral premedicant for providing effective anxiolysis in the immediate perioperative period compared to placebo."( [Preoperative subjective anxiety. Double blind study using oxazepam].
Kröll, W; List, WF; Wisiak, UV, 1988
)
1.24

Effects

Oxazepam has been shown to induce hepatocarcinogenicity in B6C3F1 mice. It has been demonstrated to slow reaction times and increase the rate of omission errors in attentional experiments. It does not form any active metabolites and has a short half-life.

ExcerptReferenceRelevance
"Oxazepam has a short half-life and inactive metabolites and therefore differs from most other benzodiazepines."( The clinical pharmacology of oxazepam.
Lader, MH, 1978
)
1.27
"Oxazepam has been subjected to controlled degradation at 100 degrees C for 3 h in 0.5 M HCl and 0.5 M NaOH. "( Characterisation of oxazepam degradation products by high-performance liquid chromatography/electrospray ionisation mass spectrometry and electrospray ionisation quadrupole time-of-flight tandem mass spectrometry.
Rodríguez Robledo, V; Smyth, TJ; Smyth, WF, 2010
)
2.13
"Oxazepam has been administered to humans by the oral route only."( Clinical pharmacokinetics of oxazepam and lorazepam.
Greenblatt, DJ,
)
1.14
"Oxazepam has been determined to be a potent hepatocarcinogen in mice. "( Activity of hepatic drug metabolizing enzymes following oxazepam-dosed feed treatment in B6C3F1 mice.
Burka, LT; Cunningham, ML; Griffin, RJ, 1995
)
1.98
"Oxazepam has been the subject of recent toxicological and carcinogenesis studies because it is a commonly prescribed tranquilizer and has been shown to cause tumors in rodents. "( Low frequency of H-ras mutations in hepatocellular adenomas and carcinomas and in hepatoblastomas from B6C3F1 mice exposed to oxazepam in the diet.
Anderson, MW; Bucher, JR; Devereux, TR; Maronpot, RR; Sills, RC; White, CM, 1994
)
1.94
"Oxazepam has recently been shown to induce hepatocarcinogenicity in B6C3F1 mice. "( Early responses of the liver of B6C3F1 mice to the hepatocarcinogen oxazepam.
Bucher, JR; Cunningham, ML; Maronpot, RR; Thompson, M, 1994
)
1.97
"Oxazepam has been demonstrated to slow reaction times and increase the rate of omission errors in attentional experiments. "( Oxazepam alters action monitoring.
Dengler, R; Johannes, S; Münte, TF; Nager, W; Wieringa, BM, 2001
)
3.2
"Oxazepam has no important active metabolites and its net disposition is minimally altered by disulfiram."( Interaction of disulfiram with benzodiazepines.
Billings, BJ; Giles, HG; Greenblatt, DJ; MacLeod, SM; Marshman, JA; Martin, PR; Sellers, EM, 1978
)
0.98
"Oxazepam has the shortest half life of the benzodiazepines and does not form any active metabolites. "( The pharmacokinetic profile of oxazepam.
Alván, G; Odar-Cederlöf, I, 1978
)
1.99
"Oxazepam has a short half-life and inactive metabolites and therefore differs from most other benzodiazepines."( The clinical pharmacology of oxazepam.
Lader, MH, 1978
)
1.27
"Oxazepam has not been associated with more or different risks than other benzodiazepines, and there is no evidence that physiological dependence occurs more frequently with oxazepam than other benzodiazepines."( Oxazepam: update 1989.
Ayd, FJ, 1990
)
2.44
"Oxazepam has little effect on the motor incoordination as compared with diazepam."( [Drug interaction of imipramine hydrochloride to the pharmacodynamics and pharmacokinetics of oxazepam].
Igarashi, T; Kitagawa, H; Ohmori, S; Okiyama, M; Ueno, K, 1987
)
1.21

Actions

Oxazepam 10 mg did not increase PUI. Did not interact with reappraisal instruction on any outcome.

ExcerptReferenceRelevance
"Oxazepam caused lower unpleasantness ratings to negative-valence stimuli, but did not interact with reappraisal instruction on any outcome."( Oxazepam and cognitive reappraisal: A randomised experiment.
Golkar, A; Howner, K; Ingvar, M; Kristiansson, M; Nilsonne, G; Olsson, A; Petrovic, P; Sörman, K; Tamm, S, 2021
)
2.79
"Oxazepam 10 mg did not increase PUI. "( Lack of sedative effects after vespertine intake of oxazepam as hypnotic in healthy volunteers.
Kellert, R; Lüdtke, H; Petrini, O; Schnell, R; Wilhelm, B, 2009
)
2.05
"Oxazepam and lorazepam inhibit the adenosine deaminase (ADA) differently. "( Kinetic and conformational studies of adenosine deaminase upon interaction with oxazepam and lorazepam.
Ahmad, F; Amanlou, M; Ataie, G; Hakimelahi, GH; Khalafi-Nezhad, A; Moosavi-Movahedi, AA; Poursasan, N; Saboury, AA; Sepassi Tehrani, H; Sharifizadeh, A; Soltani Rad, MN; Tsai, FY, 2010
)
2.03
"Oxazepam did not cause an initial increase in twitch tension, but showed an immediate and dose-dependent depression."( In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium.
Booij, LH; Crul, JF; Driessen, JJ; van Egmond, J; Vree, TB, 1984
)
1.26

Treatment

Pretreatment with oxazepam significantly attenuated methamphetamine discrimination in both male and female rats. Treatment decreased 125I-melatonin binding at 24.00 h in the hippocampus and medulla-pons of the pinealectomized rats.

ExcerptReferenceRelevance
"Oxazepam treatment decreased 125I-melatonin binding at 24.00 h in the hippocampus and medulla-pons of the pinealectomized rats and did not significantly affect the binding in the hypothalamus."( Modification by oxazepam of the diurnal variations in brain 125I-melatonin binding sites in sham-operated and pinealectomized rats.
Anis, Y; Nir, I; Schmidt, U; Zisapel, N, 1992
)
1.35
"Oxazepam treatment of primiparous mouse dams on days 12-16 of pregnancy (15 mg/kg p.o. "( Prenatal benzodiazepine effects in mice: postnatal behavioral development, response to drug challenges, and adult discrimination learning.
Alleva, E; Bignami, G, 1986
)
1.71
"Pretreatment with oxazepam (5, 10 and 20 mg/kg, ip) significantly attenuated methamphetamine discrimination in both male and female rats."( Differential modulation of the discriminative stimulus effects of methamphetamine and cocaine by alprazolam and oxazepam in male and female rats.
Goeders, NE; Guerin, GF; Spence, AL, 2016
)
0.97

Toxicity

ExcerptReferenceRelevance
" This assay is sensitive enough to detect adverse effects at low chemical concentrations and at multiple endpoints in a unique fish embryo."( An innovative and integrative assay for toxicity testing using individual fish embryos. Application to oxazepam.
Buleté, A; Cachot, J; Clérandeau, C; Daffe, G; Gonzalez, P; Granger Joly de Boissel, P; Vulliet, E, 2017
)
0.67
" Even though ozonation has proven to be very efficient in reducing pharmaceutical parent compound concentrations in wastewater effluents, much remains unclear regarding potentially toxic ozonation by-product (OBP) formation."( Embryotoxicity of ozonated diclofenac, carbamazepine, and oxazepam in zebrafish (Danio rerio).
Ahrens, L; Carlsson, G; Golovko, O; Norrgren, L; Örn, S; Pohl, J; Weiss, J, 2019
)
0.76

Pharmacokinetics

Thirty healthy male subjects were administered 15 mg of oxazepam by mouth. The pharmacodynamic effects of oxzepam were increased by the concomitant use of imipramine. These effects were in reasonably good agreement with the change in brain concentration of ox zepam.

ExcerptReferenceRelevance
" These findings and other results of pharmacokinetic research have clinical implications in terms of dosage schedules, drug accumulation during long-term therapy, antianxiety therapy in the elderly, drug interactions, pharmacotherapy in specific disease states, and the influence of route of administration on drug action."( Clinical implications of benzodiazepine pharmacokinetics.
Greenblatt, DJ; Shader, RI, 1977
)
0.26
" Its pharmacokinetic properties in healthy volunteers, uremic patients and dogs are reviewed."( The pharmacokinetic profile of oxazepam.
Alván, G; Odar-Cederlöf, I, 1978
)
0.54
" While the normal half-life (T1/2(beta)) varies between 1 and 2 days, it can be increased to up to 80--100 h in subjects over 60 years of age."( [Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)].
Klotz, U, 1978
)
0.26
" No age-related changes in the pharmacokinetic parameters of oxazepam were observed."( Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats.
Danhof, M; Hoogerkamp, A; Langemeijer, MW; Postel-Westra, I; Stijnen, AM; van Bezooijen, CF; Voskuyl, RA, 1992
)
0.78
" A possible pharmacodynamic interaction between oxazepam and the beta-adrenoceptor antagonists was examined using a simple reaction time test (SRT) and by measurement of postural sway."( Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol.
Døssing, M; Hamberg, O; Loft, S; Olesen, KL; Sonne, J; Thyssen, H; Victor, MA; Vollmer-Larsen, A, 1990
)
0.78
" The pharmacokinetics could be described by an open 2-compartment pharmacokinetic model."( Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats.
Breimer, DD; Danhof, M; Dingemanse, J; Langemeijer, MW; Meinardi, H; Postel-Westra, I; Voskuyl, RA, 1990
)
0.51
"To assess if any pharmacokinetic or pharmacodynamic interaction at steady-state occurs between the new antidepressant tianeptine and a benzodiazepine (oxazepam) following multiple oral dosing of both drugs, 12 healthy male volunteers entered a balanced three-way double blind cross-over study."( Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.
Delalleau, B; Halliday, MS; Holt, BL; Langley, SJ; Mullins, FG; Rowland, M; Salvadori, C; Toon, S, 1990
)
0.7
" In 66 first-trimester pregnant women, who had applied for legal termination of the pregnancy, we have calculated different pharmacokinetic parameters of two benzodiazepine derivatives, diazepam and oxazepam, after administration of a single oral dose of 10 or 25 mg to the mother."( Pharmacokinetics and distribution of diazepam and oxazepam in early pregnancy.
Jørgensen, NP; Thurmann-Nielsen, E; Walstad, RA, 1988
)
0.72
" The pharmacodynamic effects of oxazepam were increased by the concomitant use of imipramine, and these effects were in reasonably good agreement with the change in brain concentration of oxazepam."( [Drug interaction of imipramine hydrochloride to the pharmacodynamics and pharmacokinetics of oxazepam].
Igarashi, T; Kitagawa, H; Ohmori, S; Okiyama, M; Ueno, K, 1987
)
0.78
" We also report results on using this assay in a pharmacokinetic study of high doses of diazepam used to treat chronic schizophrenic patients."( Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics.
Moroji, T; Motomura, H; Noguchi, T; Sekiguchi, R; Tada, K, 1985
)
0.27
" The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10."( The influence of diflunisal on the pharmacokinetics of oxazepam.
de Schepper, PJ; Tjandramaga, TB; van Hecken, AM; Verbesselt, R, 1985
)
0.9
" Age and liver disease have a minimal influence on oxazepam kinetics, but renal disease is associated with a prolonged half-life and increased volume of distribution."( Clinical pharmacokinetics of oxazepam and lorazepam.
Greenblatt, DJ,
)
0.67
"The elimination half-life of chlordiazepoxide and diazepam increases with age, and this may cause prolongation of action after a single dose and delayed accumulation on multiple dosing in elderly patients."( [Pharmacokinetic of benzodiazepines in old age].
Vozeh, S, 1981
)
0.26
"Knowledge of the pharmacokinetic properties of the benzodiazepines is playing an increasingly important role in their use during pregnancy, labour and lactation."( Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.
Kanto, JH, 1982
)
0.26
"In state of tolerance to the sedative effect of nitrazepam (NTZ) its pharmacokinetic properties are changed: the absorption is slowed down, the elimination, in contrast, is accelerated due to the rapid biotransformation."( Pharmacokinetic aspects of habituation to benzodiazepines.
Cenajek, D; Chodera, A; Nowakowska, E; Szczawińska, K,
)
0.13
" Oxazepam elimination half-life was shorter and apparent oral clearance higher in untreated hyperthyroid patients than after treatment."( Oxazepam pharmacokinetics in thyroid disease.
Bewsher, PD; Hawksworth, GM; Khir, AS; Scott, AK, 1984
)
2.62
" Oxazepam elimination half-life was shorter and apparent oral clearance higher in treated patients than in age and sex matched control subjects."( Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.
Hawksworth, GM; Khir, AS; Petrie, JC; Scott, AK; Steele, WH, 1983
)
2.62
"The relative bioavailability and pharmacokinetic profile of two oxazepam preparations were evaluated in 12 normal volunteers by a newly developed HPLC-method."( [Comparative test of the bioavailability and pharmacokinetics of 2 oxazepam preparations using high-pressure liquid chromatography].
Gielsdorf, W; Hüther, KJ; Jaeger, H; Plettenberg, H, 1983
)
0.74
"03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51."( Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam.
Klotz, U; Reimann, I, 1980
)
0.49
" Cmax and AUC values based on total oxazepam in plasma were 10% lower during the night."( Lack of pharmacokinetic interaction between vinpocetine and oxazepam.
Beitinger, H; Jonkman, JH; Oosterhuis, B; Sollie, FA; Sommer, W; Storm, G; Visscher, HW, 1994
)
0.81
" Differential effects on the pharmacodynamic parameters were seen."( Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat.
Danhof, M; Hoogerkamp, A; Vis, PW; Voskuyl, RA, 1994
)
0.29
"This three-phase study was designed to determine if a pharmacokinetic drug-drug interaction exists between zidovudine and oxazepam."( Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.
Blaschke, T; Bubp, J; Israelski, D; Merigan, T; Mole, L; O'Hanley, P, 1993
)
0.73
" ND and parent OX have similar pharmacokinetic profiles."( Pharmacokinetics of nordiazepam in physical dependence and precipitated abstinence in dogs.
Martin, WR; Sloan, JW; Wala, EP, 1993
)
0.29
" This method was applied to the determination of oxazepam and its diastereoisomeric glucuronides in serum collected during a pharmacokinetic study performed in sheep after oral administration of racemic oxazepam."( Simple high-performance liquid chromatographic separation of oxazepam and its diastereoisomeric glucuronides in serum. Applications in a pharmacokinetic study in sheep.
Bressolle, F; Gagnieu, MC; Grancher, D; Mawa, R; Mis, D; Petit-Ramel, M; Vallon, JJ, 1996
)
0.79
" The pharmacodynamic parameters from these models were not altered in renal dysfunction."( Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats.
Aiba, T; Hatanaka, T; Katayama, K; Koizumi, T; Srivastava, K, 1999
)
0.55
"Several statistical regression models and artificial neural networks were used to predict the hepatic drug clearance in humans from in vitro (hepatocyte) and in vivo pharmacokinetic data and to identify the most predictive models for this purpose."( Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Coassolo, P; Lavé, T; Schneider, G, 1999
)
0.3
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
"Mirtazapine pharmacokinetic (PK) data from patients on long-term treatment for major depression have never been investigated."( Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study.
Ahlner, J; Bengtsson, F; Prochazka, J; Reis, M; Sitsen, A, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Furthermore, no differences in pharmacodynamic measures, including quantitative electroencephalography, digit-symbol substitution test, self- or observer-rated visual analogue scales, could be demonstrated for any of the polymorphisms evaluated."( Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.
Court, MH; Greenblatt, DJ; Harmatz, JS; Hazarika, S; He, X; Hesse, LM; Masse, G, 2009
)
0.72
"Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical compounds."( Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Azzara, AV; Baska, RA; Behnia, K; Carlson, KE; Cullen, MJ; Devenny, JJ; Ellsworth, BA; Everlof, GG; Ewing, WR; Godonis, HE; Gu, Z; Gudmundsson, O; Harvey, SJ; Johnghar, S; Kang, L; Keim, WJ; Lee, N; Murphy, BJ; Murugesan, N; Pelleymounter, MA; Ranasinghe, A; Rohrbach, KW; Sher, PM; Sitkoff, DF; Stetsko, PI; Sulsky, RB; Thomas, MA; Wu, G; Wu, X; Yang, Y; Yu, G; Zhu, Y; Zuvich, E, 2013
)
0.39
"According to the guidelines, benzodiazepines with a short half-life are the reference medication to treat alcohol withdrawal syndrome."( Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation?
Imbert, B; Liachenko, N; Marsot, A; Simon, N, 2016
)
0.7
" Pharmacokinetic analysis was performed using a nonlinear mixed-effect population model."( Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation?
Imbert, B; Liachenko, N; Marsot, A; Simon, N, 2016
)
0.7
"Data were modeled with a 1-compartment pharmacokinetic model."( Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation?
Imbert, B; Liachenko, N; Marsot, A; Simon, N, 2016
)
0.7
"Physiologically based pharmacokinetic (PBPK) modeling is less well established for substrates of UDP-glucuronosyltransferases (UGT) than for cytochrome P450 (CYP) metabolized drugs and more verification of simulations is necessary to increase confidence."( Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine.
Docci, L; Fowler, S; Krähenbühl, S; Parrott, N; Umehara, K, 2020
)
0.76

Compound-Compound Interactions

oxazepam glucuronyl transferase activity is increased by treatment with phenytoin alone or in combination with phenobarbitone in epileptic patients. Thus, when clinically indicated, oxazapam and lorazepAm may be the benzodiazepines of choice to use in conjunction with cimetidine to eliminate a clinically significant drug interaction.

ExcerptReferenceRelevance
" Also alcohol alone, and all the drugs in combination with alcohol retarded learning acquisition."( Effects on learning and memory of 2-week treatments with chlordiazepoxide lactam, N-desmethyldiazepam, oxazepam and methyloxazepam, alone or in combination with alcohol.
Liljequist, R; Linnoila, M; Palva, E, 1979
)
0.47
" Thus, when clinically indicated, oxazepam and lorazepam may be the benzodiazepines of choice to use in combination with cimetidine to eliminate the clinically significant drug interaction seen with diazepam and chlordiazepoxide."( Diazepam-cimetidine drug interaction: a clinically significant effect.
Ruffalo, RL; Segal, JL; Thompson, JF, 1981
)
0.54
" These results show that oxazepam glucuronyl transferase activity is increased by treatment with phenytoin alone or in combination with phenobarbitone in epileptic patients."( Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.
Hawksworth, GM; Khir, AS; Petrie, JC; Scott, AK; Steele, WH, 1983
)
2.01
"This three-phase study was designed to determine if a pharmacokinetic drug-drug interaction exists between zidovudine and oxazepam."( Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.
Blaschke, T; Bubp, J; Israelski, D; Merigan, T; Mole, L; O'Hanley, P, 1993
)
0.73
" Variables included in the analysis were age, gender, and concomitant treatment with a total of 41 drugs most often used in combination with quetiapine."( Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
Castberg, I; Skogvoll, E; Spigset, O, 2007
)
0.34
" On the basis of our data and pharmacokinetic considerations, the majority of drugs commonly used in psychiatry can safely be given in combination with quetiapine."( Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
Castberg, I; Skogvoll, E; Spigset, O, 2007
)
0.34

Bioavailability

The possible influence of food intake on the bioavailability of the anxiolytic drug oxazepam was assessed in eight healthy volunteers taking a single dose of the drug both on an empty stomach and together with a standardized breakfast meal. When meperidine was given within one hour of the dose of oxzepam the absorption was delayed but the bio availability did not decrease. At 50 mg/kg, the bio Availability of oxZepam in rats (< 50%) was lower than in Swiss-Webster mic.

ExcerptReferenceRelevance
" When meperidine was given within one hour of the dose of oxazepam the absorption was delayed but the bioavailability did not decrease."( Pharmacokinetics of oxazepam given during labour.
Lunell, NO; Rane, A; Sundwall, A; Tomson, G, 1978
)
0.83
"Four oxazepam tablet preparations and a suspension of micronized oxazepam in water were given to healthy, fasting volunteers in a comparative bioavailability study using a partial cross-over design."( Comparative bioavailability of oral dosage forms of oxazepam--correlation with in vitro dissolution rate.
Glenne, PO; Pilbrant, A; Sundwall, A; Vessman, J; Wretlind, M, 1977
)
1.02
"The possible influence of food intake on the bioavailability of the anxiolytic drug oxazepam was assessed in eight healthy volunteers taking a single dose of the drug both on an empty stomach and together with a standardized breakfast meal."( Bioavailability of oxazepam: absence of influence of food intake.
Danielson, K; Melander, A; Vessman, J; Wählin, E, 1977
)
0.81
" 10%) and its bioavailability following oral administration is about 22%."( The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs.
Martin, WR; Pruitt, TA; Sloan, JW; Wala, EP, 1990
)
0.5
" Absorption was almost complete, with a bioavailability of 92."( Bioavailability and pharmacokinetics of oxazepam.
Andreasen, F; Andreasen, PB; Døssing, M; Loft, S; Olesen, KL; Sonne, J; Victor, M; Vollmer-Larsen, A, 1988
)
0.54
"The relative bioavailability and pharmacokinetic profile of two oxazepam preparations were evaluated in 12 normal volunteers by a newly developed HPLC-method."( [Comparative test of the bioavailability and pharmacokinetics of 2 oxazepam preparations using high-pressure liquid chromatography].
Gielsdorf, W; Hüther, KJ; Jaeger, H; Plettenberg, H, 1983
)
0.74
" At 50 mg/kg, the bioavailability of oxazepam in rats (< 50%) was lower than in Swiss-Webster mice (> 80%)."( Toxicokinetics of oxazepam in rats and mice.
Clark, J; Goehl, TJ; Hong, L; Moore, R; Murrill, E; Yuan, J, 1994
)
0.9
" It was a prerequisite to establish the bioavailability of oxazepam prior to succeeding studies on the oral disposition of the drug."( Factors and conditions affecting the glucuronidation of oxazepam.
Sonne, J, 1993
)
0.78
" Explanations for the observed detrimental effect of oxazepam on implicit memory task performance are considered, including: possible time-dependent effects related to the relative rate of absorption of these two benzodiazepines (BZs); and potential contamination of the implicit memory task by explicit memory strategies during the second testing cycle."( Effects of oxazepam and lorazepam on implicit and explicit memory: evidence for possible influences of time course.
Connolly, JF; Dunphy, SC; Rioux, GF; Stewart, SH; Teehan, MD, 1996
)
0.93
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Compound 12g with MIC values of 5 μg/ml as a representative may possess better oral bioavailability and indicated high permeability by the parallel artificial membrane permeation assay of the blood-brain barrier (PAMPA-BBB)."( Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56

Dosage Studied

Pretreatment with dosed feed for 14 days resulted in a significant shift from the fecal to the urinary route of elimination. Patients were encouraged to regulate their own dosage of oxazepam.

ExcerptRelevanceReference
" Dose-response curves for locomotor activity were also determined with morphine and methadone administered intraventricularly."( Interactions between narcotic analgesics and benzodiazepine derivatives on behavior in the mouse.
Davis, DC; Holtzman, SG; Shannon, HE, 1976
)
0.26
" These findings and other results of pharmacokinetic research have clinical implications in terms of dosage schedules, drug accumulation during long-term therapy, antianxiety therapy in the elderly, drug interactions, pharmacotherapy in specific disease states, and the influence of route of administration on drug action."( Clinical implications of benzodiazepine pharmacokinetics.
Greenblatt, DJ; Shader, RI, 1977
)
0.26
" Drug dosage and time after the drug effect was measured varied."( [Comparative study on the effect of anticholinergic substances on basic gastric secretion as well as on gastric secretion stimulated by pentagastrin or hypoglycemia (author's transl)].
Brenner, U; Kutz, K; Miederer, SE; Schuler, G, 1976
)
0.26
" During multiple dosing the accumulation of conjugates was even more pronounced, with plasma concentrations amounting to 14-61 times those of oxazepam."( Oxazepam disposition in uremic patients.
Alván, G; Odar-Cederlöf, I; Sjöqvist, F; Vessman, J, 1977
)
1.9
" The three dosage forms having the highest dissolution rate in vitro were absorbed to the same extent, while slower dissolving tablets were not as fully absorbed."( Comparative bioavailability of oral dosage forms of oxazepam--correlation with in vitro dissolution rate.
Glenne, PO; Pilbrant, A; Sundwall, A; Vessman, J; Wretlind, M, 1977
)
0.51
" Bases for selection include: (1) availability of other than oral dosage forms; (2) differences in additive effect with alcohol in producing central nervous system depression; (3) differences in anticonvulsant effect; and (4) differences in duration of effect in the body (ie, half-life)."( Selection among benzodiazepines for alcohol withdrawal.
Keeler, MH; Miller, WC, 1977
)
0.26
" Recent research suggests that this is due to metabolic and pharmacokinetic differences rather than an intrinsically more favourable toxic-to-therapeutic dosage ratio."( The clinical activity of oxazepam.
Cardon, A; Fouks, L; Pinalie, B; Porcheron, JB, 1978
)
0.56
" Dose-response related decrements in male sexual behavior were observed following chlorpromazine and chlordiazepoxide."( Effects of chlordiazepoxide, oxazepam, chlorpromazine, and d-amphetamine on sexual responses in male and female hamsters.
Carter, CS; Daily, RF; Leaf, R, 1977
)
0.55
" We report five cases of high-dose triazolam abuse in which the daily dosage ranged from 5 to 15 mg (100-300 mg diazepam equivalent) and the duration of use ranged from 3 months to 5 years."( Detoxification for triazolam physical dependence.
Sellers, EM; Sullivan, JT, 1992
)
0.28
" The dose-response curve with the dissociation constant 2 x 10(-3) mol/l was obtained."( [Taurine-activated currents in isolated neurons of the rat cerebellum].
Dashkin, AN; Garashchuk, OA; Valeev, AE, 1990
)
0.28
"To assess if any pharmacokinetic or pharmacodynamic interaction at steady-state occurs between the new antidepressant tianeptine and a benzodiazepine (oxazepam) following multiple oral dosing of both drugs, 12 healthy male volunteers entered a balanced three-way double blind cross-over study."( Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.
Delalleau, B; Halliday, MS; Holt, BL; Langley, SJ; Mullins, FG; Rowland, M; Salvadori, C; Toon, S, 1990
)
0.7
"The dose-response relationships of diazepam and several of its metabolites were determined in rats trained to discriminate diazepam (3 mg/kg) from saline in a two-lever operant choice task."( Potencies of diazepam metabolites in rats trained to discriminate diazepam.
Brase, DA; Dewey, WL; Glennon, RA; Young, R, 1986
)
0.27
" Flumazenil caused dose-related increases in the NPAS scores of both diazepam- and nordiazepam-dependent dogs; the slopes of the two dose-response lines were not different."( Precipitation of abstinence in nordiazepam- and diazepam-dependent dogs.
Martin, WR; McNicholas, LF; Sloan, JW; Wala, E, 1988
)
0.27
"The advent of several new column materials for the resolution of chiral compounds in high-performance liquid chromatography has opened up new possibilities for the analysis of drug enantiomers both in the dosage form and in bioanalytical studies."( Computer-aided optimisation of drug enantiomer separation in chiral high-performance liquid chromatography.
Clark, BJ; Fell, AF; Mama, JE; Noctor, TA, 1988
)
0.27
"Five healthy elderly volunteers aged 64 to 67 years and 12 healthy young subjects aged 23 to 44 years received single 30 mg oral doses of oxazepam in two different dosage forms (two 15 mg tablets or one 30 mg capsule) on two occasions in a random crossover sequence, with at least 1 week elapsing between trials."( Kinetics and dynamics of single doses of oxazepam in the elderly: implications of absorption rate.
Dreyfuss, D; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1986
)
0.74
"Dogs, surgically implanted with a chronic gastric fistula, were chronically dosed with N-desmethyldiazepam (32 mg/kg/day) in four divided doses to attain N-desmethyldiazepam plasma levels comparable to those observed in dogs dependent on diazepam (60 mg/kg/day)."( N-desmethyldiazepam physical dependence in dogs.
Martin, WR; McNicholas, LF; Pruitt, TA, 1985
)
0.27
"The elimination half-life of chlordiazepoxide and diazepam increases with age, and this may cause prolongation of action after a single dose and delayed accumulation on multiple dosing in elderly patients."( [Pharmacokinetic of benzodiazepines in old age].
Vozeh, S, 1981
)
0.26
"Three different dosage studies were carried out with midazolam in 47 institutionalized geriatric patients (17 males: mean age 82."( Midazolam dosage studies in institutionalized geriatric patients.
Beck, H; Holzer, J; Salom, M, 1983
)
0.27
" for 14 days) the corresponding dose-response lines were shifted to the right suggesting tolerance development."( Subacute benzodiazepine treatment: observations on behavioural tolerance and withdrawal.
Gonzalez, JP; McCulloch, AJ; Nicholls, PJ; Sewell, RD; Tekle, A, 1984
)
0.27
"A new formulation of oxazepam especially designed to increase the speed of absorption and eliminate the need to use water (freeze-dried dosage formulation; FDDF) was compared in double-blind and crossover conditions with the standard tablets of the same compound."( Self-reports of anxiety level and EEG changes after a single dose of benzodiazepines. Double-blind comparison of two forms of oxazepam.
Ansseau, M; Cerfontaine, JL; Doumont, A; Mantanus, H; Rousseau, JC; Timsit Berthier, M, 1984
)
0.79
" Thus, the differing pharmacokinetic profiles of diazepam and oxazepam have clinical consequences during multiple dosage in the elderly."( Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam.
Greenblatt, DJ; Harmatz, JS; Salzman, C; Shader, RI, 1983
)
0.72
" Our findings confirm that FPDC is responsive to benzodiazepine therapy and suggest that an alternate-day dosing schedule, using a short-acting benzodiazepine, may minimize receptor down regulation and thereby sustain the therapeutic effect."( Familial paroxysmal dystonic choreoathetosis and response to alternate-day oxazepam therapy.
Kurlan, R; Shoulson, I, 1983
)
0.5
" 83--92% of the dosage are eliminated via urine."( Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease.
Bozler, G; Busch, U; Koss, FW; Molzahn, M, 1981
)
0.59
" Patients were encouraged to regulate their own dosage of oxazepam, and no difficulties occurred with this technique."( Oxazepam in the treatment of anxiety associated with depression: results of treatment in 1600 cases (Studies in depression, VI).
Bailey, HR; Davies, E; Morrison, IJ, 1981
)
1.95
" Oxazepam was undialyzable; since unbound oxazepam disposition kinetics are not altered, no dosage adjustment for patients is necessary."( Renal disease, age, and oxazepam kinetics.
Chiang, ST; Koepke, HH; Murray, TG; Walker, BR, 1981
)
1.48
" The rate of elimination for all three routes of elimination was elevated by dosed feed treatment."( Metabolism and elimination of oxazepam in F344 rats.
Burka, LT; Griffin, RJ, 1995
)
0.58
"The present dose-response study investigated the effects of the benzodiazepine oxazepam (Serax) on anxiety as measured by autonomic and self-report indices in a nonclinical sample."( Effects of oxazepam on anxiety: implications for Fowles' psychophysiological interpretation of Gray's model.
Landon, JF; Shah, JH; Sher, KJ, 1993
)
0.9
" After oral gavage dosing the peak oxazepam plasma concentrations in most rodents were reached within 2-3."( Toxicokinetics of oxazepam in rats and mice.
Clark, J; Goehl, TJ; Hong, L; Moore, R; Murrill, E; Yuan, J, 1994
)
0.9
" Pretreatment with dosed feed for 14 days (to model autoinduction in bioassay animals) resulted in a significant shift from the fecal to the urinary route of elimination, an approximately 2-fold increase in elimination of oxazepam glucuronide, and a significant decrease in excretion of unchanged oxazepam."( Metabolism and elimination of oxazepam in B6C3F1 and Swiss-Webster mice.
Burka, LT; Griffin, RJ,
)
0.6
" Phase III began with 48 h of concomitant zidovudine, 100 mg orally every 4 h, and oxazepam, 15 mg orally every 8 h, followed by concomitant dosing of intravenous zidovudine and oral oxazepam."( Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.
Blaschke, T; Bubp, J; Israelski, D; Merigan, T; Mole, L; O'Hanley, P, 1993
)
0.75
"A computer model for predicting blood/plasma concentrations of test chemicals in dosed feed and dosed drinking water toxicology studies was developed."( Modeling blood/plasma concentrations in dosed feed and dosed drinking water toxicology studies.
Yuan, J, 1993
)
0.29
" Drug was most often given on a fixed dosing schedule with additional medication "as needed" (52% of the programs)."( Alcohol withdrawal: a nationwide survey of inpatient treatment practices.
Friedman, LS; Mayo-Smith, MF; Saitz, R, 1995
)
0.29
" A similar pattern of biochemical events has been observed to occur during dosed feed treatment with phenobarbital."( Biochemical effects of the mouse hepatocarcinogen oxazepam: similarities to phenobarbital.
Cunningham, ML; Dudley, CN; Griffin, RJ, 1996
)
0.55
" Group B patients (20) were treated by tapering of oxazepam dosage (from 120 mg) and with saline solution (as placebo) instead of FLU for 8 days."( Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study.
Brewer, C; Gerra, G; Giusti, F; Moi, G; Zaimovic, A, 2002
)
0.86
" PB produced a twofold increase in liver MF over controls after 27 weeks of treatment, but a similar increase was not observed with longer dosing times; at later time points, the MF in the PB groups was lower than that of the control group, suggesting that PB is not producing direct DNA damage in the liver."( Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice.
de Boer, J; Fairchild, D; Glickman, B; Johnson, A; Kanazawa, N; Mirsalis, JC; Nguyen, T; Shimon, JA; Winegar, RA, 2005
)
0.33
" The effects of an additional 20-mg dosage oxazepam were assessed in a double-blind, balanced-order, crossover randomized study comparing 16 long-term users of oxazepam (patients) with 18 benzodiazepine-naive controls (controls)."( Effects of additional oxazepam in long-term users of oxazepam.
Edelbroek, PM; van Luijtelaar, GL; Verkes, RJ; Voshaar, RC; Zitman, FG, 2005
)
0.91
" The dosage was increased to 10 mg daily two weeks later."( Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Brahm, NC; Brown, RC; McElwain, DL, 2007
)
0.34
"Biological samples were collected from eight male subjects after ingestion of 15 or 30 mg oxazepam on separate dosing occasions with an interval of 7 days."( The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam.
de Gier, JJ; Dijkhuizen, A; Egberts, AC; Hofman, BJ; Lusthof, KJ; Smink, BE; Uges, DR, 2008
)
0.89
"It is necessary to warn patients who take benzodiazepines in therapy that reinforcement of irritability may occur in case of higher dosage of benzodiazepines, which may be misinterpreted as worsening in mental condition."( Reinforcement of irritability during therapy with benzodiazepines.
Kozumplik, O; Uzun, S, 2011
)
0.37
"12mg/kg/infusion) were tested, producing an inverted U-shaped dose-response curve."( The differential effects of alprazolam and oxazepam on methamphetamine self-administration in rats.
Goeders, NE; Guerin, GF; Spence, AL, 2016
)
0.7
"Oxazepam significantly reduced methamphetamine self-administration as demonstrated by a downward shift of the dose-response curve."( The differential effects of alprazolam and oxazepam on methamphetamine self-administration in rats.
Goeders, NE; Guerin, GF; Spence, AL, 2016
)
2.14
"The present study involved segmental testing of hair in two clinical cases with known dosage histories."( Segmental Hair Analysis-Interpretation of the Time of Drug Intake in Two Patients Undergoing Drug Treatment.
Johansen, SS; Linnet, K; Nielsen, MKK; Wang, X, 2019
)
0.51
" Data extracted included information about study design, country of origin, number of participants and demographic details, type of surgery, type of anaesthesia, intervention and dosing regimens, preoperative anxiety outcome measures, and postoperative anxiety outcome measures."( Melatonin for preoperative and postoperative anxiety in adults.
Madsen, BK; Møller, AM; Rosenberg, J; Zetner, D, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1,4-benzodiazepinone
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency39.20660.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency16.68300.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency21.65120.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743040; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency69.14800.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency55.29060.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency39.24290.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency52.62880.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency13.92390.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency54.92480.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency42.47520.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.47000.000229.305416,493.5996AID743078; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency35.08800.001019.414170.9645AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency68.51990.000723.06741,258.9301AID743085
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency47.53270.000323.4451159.6830AID743065; AID743067
lamin isoform A-delta10Homo sapiens (human)Potency0.44670.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Translocator proteinHomo sapiens (human)IC50 (µMol)55,590.39840.00030.13020.4900AID40987
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd69.18310.08933.31358.0000AID327170
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
protein targeting to mitochondrionTranslocator proteinHomo sapiens (human)
C21-steroid hormone biosynthetic processTranslocator proteinHomo sapiens (human)
heme biosynthetic processTranslocator proteinHomo sapiens (human)
monoatomic anion transportTranslocator proteinHomo sapiens (human)
chloride transportTranslocator proteinHomo sapiens (human)
steroid metabolic processTranslocator proteinHomo sapiens (human)
glial cell migrationTranslocator proteinHomo sapiens (human)
response to xenobiotic stimulusTranslocator proteinHomo sapiens (human)
response to manganese ionTranslocator proteinHomo sapiens (human)
response to vitamin B1Translocator proteinHomo sapiens (human)
peripheral nervous system axon regenerationTranslocator proteinHomo sapiens (human)
sterol transportTranslocator proteinHomo sapiens (human)
adrenal gland developmentTranslocator proteinHomo sapiens (human)
negative regulation of protein ubiquitinationTranslocator proteinHomo sapiens (human)
regulation of cholesterol transportTranslocator proteinHomo sapiens (human)
response to progesteroneTranslocator proteinHomo sapiens (human)
negative regulation of tumor necrosis factor productionTranslocator proteinHomo sapiens (human)
response to testosteroneTranslocator proteinHomo sapiens (human)
regulation of cell population proliferationTranslocator proteinHomo sapiens (human)
cholesterol homeostasisTranslocator proteinHomo sapiens (human)
positive regulation of apoptotic processTranslocator proteinHomo sapiens (human)
negative regulation of nitric oxide biosynthetic processTranslocator proteinHomo sapiens (human)
behavioral response to painTranslocator proteinHomo sapiens (human)
regulation of steroid biosynthetic processTranslocator proteinHomo sapiens (human)
positive regulation of mitochondrial depolarizationTranslocator proteinHomo sapiens (human)
positive regulation of calcium ion transportTranslocator proteinHomo sapiens (human)
contact inhibitionTranslocator proteinHomo sapiens (human)
positive regulation of glial cell proliferationTranslocator proteinHomo sapiens (human)
negative regulation of glial cell proliferationTranslocator proteinHomo sapiens (human)
positive regulation of programmed necrotic cell deathTranslocator proteinHomo sapiens (human)
cellular response to lipopolysaccharideTranslocator proteinHomo sapiens (human)
cellular response to zinc ionTranslocator proteinHomo sapiens (human)
cellular hypotonic responseTranslocator proteinHomo sapiens (human)
maintenance of protein location in mitochondrionTranslocator proteinHomo sapiens (human)
negative regulation of mitophagyTranslocator proteinHomo sapiens (human)
negative regulation of ATP metabolic processTranslocator proteinHomo sapiens (human)
response to acetylcholineTranslocator proteinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processTranslocator proteinHomo sapiens (human)
negative regulation of corticosterone secretionTranslocator proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
androgen bindingTranslocator proteinHomo sapiens (human)
protein bindingTranslocator proteinHomo sapiens (human)
benzodiazepine receptor activityTranslocator proteinHomo sapiens (human)
cholesterol bindingTranslocator proteinHomo sapiens (human)
transmembrane transporter bindingTranslocator proteinHomo sapiens (human)
cholesterol transfer activityTranslocator proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
mitochondrionTranslocator proteinHomo sapiens (human)
mitochondrial outer membraneTranslocator proteinHomo sapiens (human)
cytosolTranslocator proteinHomo sapiens (human)
intracellular membrane-bounded organelleTranslocator proteinHomo sapiens (human)
extracellular exosomeTranslocator proteinHomo sapiens (human)
endoplasmic reticulumTranslocator proteinHomo sapiens (human)
membraneTranslocator proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (220)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID21859In vivo clearance in rat.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID21851In vitro clearance in human in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1136395Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of maximal electric shock-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1427528Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1360444Binding affinity to human serum albumin assessed as fraction unbound after 4 hrs by LC-MS method2018European journal of medicinal chemistry, Jul-15, Volume: 155Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID624652Inhibition of ciramadol glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1437174Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1625123Permeability of the compound in pH 7.4 PBS at 200 uL after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID127663Compound was evaluated for the antimetrazole effect by administering through intravenous route at the pretreatment period of 240 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1130726Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for behavioral activity in po dosed albino Swiss-Webster mouse by fighting test1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID327170Binding affinity to human serum albumin by PAMPA method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID23479Partition coefficient (logP)1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID1374215Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID21857In vivo clearance in human.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1557178Permeability of the compound at 100 ug/ml measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1496041Effective permeability of the compound by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1465314Effective permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1890739Permeability of the compound across blood brain barrier incubated for 18 hrs by UV plate reader based PAMPA assay2022Bioorganic & medicinal chemistry, 04-15, Volume: 60Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624641Inhibition of 4-methylumbelliferone glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1130721Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of minimum electro shock-induced seizure1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1334753Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID127695Compound was evaluated for the muscle relaxant effect by administering through intravenous route at the pretreatment period of 120 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1131184Antimetrazol activity in iv dosed mouse assessed as inhibition of metrazol-induced tonic-extensor seizures administered 30 mins prior to metrazol challenge1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 1. Correlation between hydrolysis rates and brain appearance of oxazepam.
AID1136396Antidepressant activity in ip dosed albino CF-1 mouse assessed as inhibition of ethanol-induced response1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1444094Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1131186Muscle relaxant activity in iv dosed mouse after 30 mins by rotarod test1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 1. Correlation between hydrolysis rates and brain appearance of oxazepam.
AID1533612Effective permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID1390040Effective permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1360429Binding affinity to human serum albumin after 4 hrs by LC-MS method2018European journal of medicinal chemistry, Jul-15, Volume: 155Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1517867Permeability of compound by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID127696Compound was evaluated for the muscle relaxant effect by administering through intravenous route at the pretreatment period of 20 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID129367Oxazepam brain level after 30 minutes of administration of 0.75 mg/kg in muscle relaxant assay1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID127830Compound was evaluated for the muscle relaxant effect by administering through intravenous route at the pretreatment period of 5 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1138124Washout half life in human2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
AID1465293Effective permeability of the compound at 100 ug/ml by PAMPA-BBB assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1130727Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for hypnotic activity in po dosed albino Swiss-Webster mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID1533611Effective permeability of the compound by PAMPA2019European journal of medicinal chemistry, Feb-01, Volume: 163Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1568822Effective permeability of the compound at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID129370Oxazepam brain level after 5 minutes of administration of 0.96 mg/kg in muscle relaxant assay1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1453097Effective permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1427527Effective permeability of the compound at pH 7.4 after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1131208Ratio of ED50 for muscle relaxant activity in mouse to ED50 for antimetrazol activity in mouse measured after 60 mins1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 1. Correlation between hydrolysis rates and brain appearance of oxazepam.
AID1292330Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1130724Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for muscle relaxing activity in po dosed albino Swiss-Webster mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID127697Compound was evaluated for the muscle relaxant effect by administering through intravenous route at the pretreatment period of 240 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1727019Half life in human2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1585850Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1660982Inhibition of Escherichia coli Stx2 in human HeLa cells assessed as stimulation of protein synthesis by measuring increase in [14C]-leucine incorporation at 30 uM incubated with cells for 4 hrs prior to Stx2 addition and further incubated for 20 hrs and s2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Structure-Activity Relationship Studies of Retro-1 Analogues against Shiga Toxin.
AID1130720Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of maximum electro shock-induced seizure1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1131230Binding affinity to human serum albumin at 10 uM after 12 to 20 hrs by scintillation spectrometry1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 2. Correlation of hydrophobicity with serum binding, brain penetration, and excretion.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1436078Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID327169Apparent permeability across parallel artificial membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1136388Effect on motor activity in ip dosed albino CF-1 mouse by chimney test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID26380Dissociation constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1136390Effect on motor activity in ip dosed albino CF-1 mouse by pedestal test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1570001Permeability of compound at 100 ug/ml measured after dilution with PBS/EtOH (70:30) at pH 7.4 after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID127660Compound was evaluated for the antimetrazole effect by administering through intravenous route at the pretreatment period of 10 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID129372Oxazepam brain level after 60 minutes of administration of 0.39 mg/kg in antimetrazole assay1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID129363Oxazepam brain level after 240 minutes of administration of 0.62 mg/kg in antimetrazole assay1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1383661Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
AID1436079Permeability of compound at 25 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID1292332Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1625122Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1336731Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1136394Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of strychnine-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID127664Compound was evaluated for the antimetrazole effect by administering through intravenous route at the pretreatment period of 5 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1529187Binding affinity to human serum albumin assessed as change in dissociation constant pKa2 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID127661Compound was evaluated for the antimetrazole effect by administering through intravenous route at the pretreatment period of 120 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1517838Permeability of the compound in pH 7.4 PBS/EtOH at 25 ug/ml after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1131187Muscle relaxant activity in iv dosed mouse after 60 mins by rotarod test1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 1. Correlation between hydrolysis rates and brain appearance of oxazepam.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID11307291-Octanol-aqueous phosphate buffer partition coefficient, log P of the compound at pH 7.351979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID29363Dissociation constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1437175Permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1568812Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1552590Permeability of compound at 25 ug/ml at pH 7.4 incubated for 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1390042Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1334754Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID1136391Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of nicotine-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID194132Fourfod increase in lever pressing in punished rats, ED50 value reported as log1/C1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1131188Ratio of ED50 for muscle relaxant activity in mouse to ED50 for antimetrazol activity in mouse measured after 30 mins1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 1. Correlation between hydrolysis rates and brain appearance of oxazepam.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1192731Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID1192730Permeability of the compound by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1130718Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of pentylenetetrazole-induced seizure1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID599144Intrinsic solubility, log 1/S0 of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624656Inhibition of morphine glucuronidation by human fetal-liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1136393Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of thiosemicarbazide-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID624647Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID129365Oxazepam brain level after 30 minutes of administration of 0.18 mg/kg in antimetrazole assay1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID129374Oxazepam brain level after 60 minutes of administration of 1.60 mg/kg in muscle relaxant assay1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID127662Compound was evaluated for the antimetrazole effect by administering through intravenous route at the pretreatment period of 20 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1136397Anxiolytic activity in ip dosed albino CF-1 mouse under hypoxic stress1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1131228Fraction unbound in 22% albino mouse serum at 10 uM by equilibrium dialysis method in presence of diisopropyl fluorophosphate1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 2. Correlation of hydrophobicity with serum binding, brain penetration, and excretion.
AID1136387Effect on motor activity in ip dosed albino CF-1 mouse by traction test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1130728Toxicity in po dosed albino Swiss-Webster mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID194131ED50 value was reported as log1/C, which is the concentration required to reduce locomotor activity by 50% in rats1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID129361Oxazepam brain level after 10 minutes of administration of 0.86 mg/kg in muscle relaxant assay1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1136389Effect on motor activity in ip dosed albino CF-1 mouse by dish test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1557184Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID40994Binding affinity towards benzodiazepine/GABA A receptor.1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks.
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID237585Tested for fraction of oral dose absorbed orally in humans2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1496040Effective permeability of the compound in PBS/EtOH at 50 ug/mL after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID1374214Effective permeability of the compound in pH 7.4 buffer after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID194134Halving of lever pressing in non punished rats, ED50 value reported as log 1/C1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID40987Binding affinity of compound towards Benzodiazepine receptor in a competition assay1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID21852In vitro clearance in rat in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21849In vitro clearance in dog in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1136392Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of pentylenetetrazole-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1585851Effective permeability of the compound by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1444095Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1529185Protein binding in human serum albumin after 4.5 hrs by LC-MS based rapid equilibrium dialysis method2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID21854In vivo clearance in dog.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1131185Antimetrazol activity in iv dosed mouse assessed as inhibition of metrazol-induced tonic-extensor seizures administered 60 mins prior to metrazol challenge1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Oxazepam esters. 1. Correlation between hydrolysis rates and brain appearance of oxazepam.
AID127694Compound was evaluated for the muscle relaxant effect by administering through intravenous route at the pretreatment period of 10 min1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,272)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990778 (61.16)18.7374
1990's192 (15.09)18.2507
2000's133 (10.46)29.6817
2010's142 (11.16)24.3611
2020's27 (2.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 102.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index102.27 (24.57)
Research Supply Index7.38 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index189.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (102.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials229 (16.68%)5.53%
Reviews58 (4.22%)6.00%
Case Studies92 (6.70%)4.05%
Observational4 (0.29%)0.25%
Other990 (72.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome [NCT02090504]Phase 4127 participants (Actual)Interventional2002-02-28Completed
MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers [NCT02570581]Phase 116 participants (Actual)Interventional2014-06-30Completed
A Phase 1b, Randomized, Double-Blinded, Multiple-Dose, Placebo Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetic Effects Of A Metyrapone And Oxazepam Combination (EMB-001) When Co-Administered With Cocaine [NCT02856854]Phase 118 participants (Actual)Interventional2016-07-31Completed
A Randomised, Double-blind, Double-dummy, Placebo-controlled Cross-over Trial to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets (120 mg Valerian / 80 mg Lemon Balm) [NCT02273453]Phase 154 participants (Actual)Interventional2003-02-28Completed
A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Metyrapone and Oxazepam in the Treatment of Cocaine Addiction [NCT00567814]45 participants (Anticipated)Interventional2007-12-31Completed
Phase 1 Combined Single and Multiple Rising Dose Study of the Safety and Pharmacokinetics of Metyrapone/Oxazepam Combination (EMB-001) [NCT02406066]Phase 124 participants (Actual)Interventional2015-03-31Completed
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient [NCT00000661]Phase 18 participants InterventionalCompleted
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment [NCT04868253]Phase 2/Phase 325 participants (Anticipated)Interventional2021-05-19Recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]